The European healthcare technology and medical device landscape has reached a definitive inflection point in 2026, transitioning from a decade of speculative, venture subsidised experimentation to an era of disciplined industrial maturity. This transition is characterised by a fundamental shift away from the liquidity fuelled exuberance of the early 2020s toward a metrics driven environment where strategic value is defined by clinical utility, regulatory resilience and tec